Clinical trial · Observational
Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
OS09328 Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors
NCT01063400CI-TRIAL-00006262terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): lack of funding
Summary
Brief summary (as posted)
The purpose of this research is to examine the relationship between performance status rating and the actual amount of physical activity a subject does when it is measured by an activity monitor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Activity monitoring
- interventionNames
- Other: Observation
Primary outcomes (1)
- measure
- To determine the feasibility of examining physical activity (through objective measurement devices) and performance status in a 14-day study of lung cancer patients.
- timeFrame
- 14 days
Secondary outcomes (1)
- measure
- To determine the number of days of monitoring necessary to reliably estimate energy expenditure (steps/day, and % of time spent sedentary) in lung cancer patients undergoing chemotherapy.
- timeFrame
- 14 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Worst Daily Pain rating of \< 4/10 * ECOG Performance Status of 0, 1, or 2 * Prior malignancy is allowed as long as it is inactive or well-controlled without current anti-tumor therapy required Exclusion Criteria: * Known brain metastasis * Use of assistive devices (cane, crutch) * No concurrent radiotherapy: all radiotherapy must be completed 4 weeks prior to enrollment in this study * Patients receiving only targeted therapy are not eligible(e.g.erlotinib)
References
Publications (0)
Data not yet available
No reference posted for this study.